Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase III IMpower030 trial.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
